Mission Viejo, CA, United States of America

Clarence Eugene Hull, Iii

This inventor holds 14 USPTO granted patents and 1 published patent application, primarily in Kinase Inhibitors. Top assignees: Allergan, Inc., Allergan Sales, Inc.. Active years: 2003-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clarence Eugene Hull, Iii. Retrieved from https://idiyas.com/inventor/clarence-eugene-hull-iii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 1)

% Patents Active = 92.9

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 91(Granted Patents)

Location History:

Aliso Viejo, CA (US) (2003 - 2006)
Trabaco Canyon, CA (US) (2006)
Trabuco Canyon, CA (US) (2004 - 2011)
Mission Viejo, CA (US) (2014 - 2017)

Company Filing History:

Years Active: 2003-2017

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Protein Kinase

Vascular Endothelial Growth Factor

Pyrimidine Derivatives

Sulfoximines

Tetrahydropyrido

Naphthyridines

Disease Treatment

Modulators

Amino Compounds

Indol-2-Ones

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9820989 - Method of treating conditions with kinase inhibitors (2017-11-21),

2. 9388181 - Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase (2016-07-12),

3. 9388176 - Method of treating conditiions with kinase inhibitors (2016-07-12),

4. 9365575 - Kinase inhibitors (2016-06-14),

5. 9321766 - Kinase inhibitors (2016-04-26),

6. 9296747 - Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 (2016-03-29),

7. 9255096 - Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors (2016-02-09),

8. 8889870 - Kinase inhibitors (2014-11-18),

9. 7915443 - Sulfoximines as kinase inhibitors (2011-03-29),

10. 7531665 - Kinase inhibitors for the treatment of disease (2009-05-12),

11. 7098236 - 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors (2006-08-29),

12. 7060844 - (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors (2006-06-13),

13. 6747025 - Kinase inhibitors for the treatment of disease (2004-06-08),

14. 6541504 - (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors (2003-04-01),

Title: Inventor Clarence Eugene Hull, III

Introduction: Clarence Eugene Hull, III is a renowned inventor based in Mission Viejo, California. He is known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Clarence Eugene Hull, III holds several patents in the areas of technology, healthcare, and environmental sustainability. His recent patents focus on improving renewable energy sources and enhancing medical devices for better patient outcomes.

Career Highlights: With a career spanning over two decades, Clarence Eugene Hull, III has established himself as a leading figure in the world of innovation. He has worked with top research institutions and companies to bring his ideas to life and make a positive impact on society.

Collaborations: Throughout his career, Clarence Eugene Hull, III has collaborated with fellow inventors, scientists, and engineers to push the boundaries of what is possible. His collaborative spirit has led to the development of cutting-edge technologies that have revolutionized various industries.

Conclusion: In conclusion, Clarence Eugene Hull, III's passion for innovation and his dedication to creating a better future through his inventions have solidified his reputation as a visionary inventor. His work continues to inspire the next generation of inventors to think outside the box and strive for excellence in their pursuits.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent pending: